AbbVie employs MC10's wearables for new MS clinical trials
Summary
The pair plan to use MC10’s FDA cleared wearable sensor technology, dubbed the BioStamp nPoint system, to help keep track of a patient’s physiological data and outcomes during the trials. The flexible and stretchable electronic sensors landed FDA clearance last year to record vital signs like movement and heart rate and display them on an Android phone provided by MC10. Last week Verily announced a series of new strategic partnerships with four global pharmaceutical companies that will bring low-burden digital data collection and analysis tools to clinical research projects. “We are excited to explore the BioStamp nPoint System’s ability to unobtrusively collect clinically relevant data continuously from subjects in more natural settings. This technology has the potential to improve the quality of data we collect and at the same time reduce the burden on study participants,” Dr. Michael Gold, VP of development neurosciences at AbbVie, said in a statement.
Classifications
AskAI Classifications
LabelsLinked Companies
